Prescription Drug Pricing
Expert articles and analysis related to prescription drug pricing.
AI Summary — Last 24 Hours
CMS has delayed the Part D portion of the BALANCE Model aimed at expanding GLP-1 access, responding to insurer skepticism about financial and operational risks, which poses new uncertainties for population health management and value-based care models dependent on predictable drug costs. This comes as CMS finalizes sweeping changes to Medicare Advantage and Part D regulations for 2027, heightening near-term strategic tension for ACOs and payers seeking clarity on drug pricing and benefit design amid persistent cost pressures and anticipated hospital margin declines.
Related Articles
US reveals new Medicare prices for second round of IRA drugs
From newsletter: The LI Daily: GoodRx launches direct-to-employer platform aimed at lowering drug costs; 15 more high-profile drugs for IRA price negotiations GoodRx launches direct-to-employer plat...
Explaining the Prescription Drug Provisions in the Inflation Reduction Act | KFF
From newsletter: The LI Daily: GoodRx launches direct-to-employer platform aimed at lowering drug costs; 15 more high-profile drugs for IRA price negotiations GoodRx launches direct-to-employer plat...
Senate Democrats target Trump drug deals with transparency bill
Senate Democrats target Trump drug deals with transparency bill Becker's Hospital Review
What mid-size PBMs fear from Labor’s transparency mandates
What mid-size PBMs fear from Labor’s transparency mandates Modern Healthcare
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid KFF
FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral
FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral MedCity News
Washington Post publishes AHA letter in response to anti-340B editorial
Washington Post publishes AHA letter in response to anti-340B editorial American Hospital Association
Amazon rolls out GLP-1 program for One Medical patients
Amazon rolls out GLP-1 program for One Medical patients Modern Healthcare
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.
Amazon One Medical launches weight management program including GLP-1 drugs
The company argues the offering is a more comprehensive approach to weight management, allowing patients to receive ongoing support care and transparent pricing on prescriptions.